Yunkang Group’s 2025 Interim Net Loss Narrows, Demonstrating Strong Operational Resilience
HONG KONG, Aug 29, 2025 – (ACN Newswire via SeaPRwire.com) – Yunkang Group Limited (“Yunkang” or the “Group”; Stock Code: 2325), a leading medical operation services provider in China, has announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”). The Group adopted “one horizontal, one vertical” as its core business strategy: horizontally, it extended a lean management system to advance multi-mode collaboration among medical institution alliances; vertically, it focused on specialty-specific innovation in medical diagnostics to fast-track the translation and implementation of new technologies and products. Meanwhile, the Group leveraged AI to enhance the comprehensive solutions for medical institution alliances, promoted the practical application of AI in healthcare scenarios, and continuously strengthened the value of empowering clinical practices, demonstrating strong operational resilience.In the first half of 2025, due to multiple factors, including the centralized drug-…